Thomas Catinazzo Relay Therapeutics, Inc. (RLAY) insider trading activity

Thomas Catinazzo is Chief Financial Officer of Relay Therapeutics, Inc.. Currently has a direct ownership of 379,431 shares of RLAY, which is worth approximately $1.76 Million. The most recent transaction as insider was on Jan 30, 2025, when has been sold 20,791 shares (Common Stock) at a price of $4.42 per share, resulting in proceeds of $91,896. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 379K

24.78% 3M change

10.99% 12M change

Total Value Held $1.76 Million

Thomas Catinazzo Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jan 30 2025	SELL Open market or private sale	$91,896 $4.42 p/Share	20,791 Reduced 5.19%	379,431 Common Stock
Jan 29 2025	SELL Open market or private sale	$9,595 $4.55 p/Share	2,109 Reduced 0.52%	400,222 Common Stock
Jan 28 2025	SELL Open market or private sale	$166,846 $4.63 p/Share	36,036 Reduced 12.04%	263,190 Common Stock
Jan 28 2025	BUY Grant, award, or other acquisition	-	139,141 Added 25.7%	402,331 Common Stock
Dec 27 2024	SELL Open market or private sale	$21,406 $4.4 p/Share	4,865 Reduced 1.6%	299,226 Common Stock
Oct 29 2024	SELL Open market or private sale	$13,685 $5.95 p/Share	2,300 Reduced 0.75%	304,091 Common Stock
Oct 28 2024	SELL Open market or private sale	$41,220 $6.06 p/Share	6,802 Reduced 2.17%	306,391 Common Stock
Sep 27 2024	SELL Open market or private sale	$48,362 $7.49 p/Share	6,457 Reduced 2.02%	313,193 Common Stock
Jul 29 2024	SELL Open market or private sale	$93,570 $8.68 p/Share	10,780 Reduced 3.26%	319,650 Common Stock
Jun 27 2024	SELL Open market or private sale	$58,581 $6.25 p/Share	9,373 Reduced 2.76%	330,430 Common Stock
Apr 29 2024	SELL Open market or private sale	$10,814 $6.38 p/Share	1,695 Reduced 0.5%	339,803 Common Stock
Mar 27 2024	SELL Open market or private sale	$2,679 $7.7 p/Share	348 Reduced 0.1%	341,498 Common Stock
Jan 29 2024	SELL Open market or private sale	$19,328 $9.64 p/Share	2,005 Reduced 0.58%	341,846 Common Stock
Jan 16 2024	BUY Grant, award, or other acquisition	-	200,000 Added 36.77%	343,851 Common Stock
Dec 27 2023	SELL Open market or private sale	$3,383 $11.51 p/Share	294 Reduced 0.2%	143,851 Common Stock
Oct 30 2023	SELL Open market or private sale	$10,232 $6.03 p/Share	1,697 Reduced 1.16%	144,145 Common Stock
Sep 27 2023	SELL Open market or private sale	$2,463 $8.38 p/Share	294 Reduced 0.2%	145,842 Common Stock
Jul 28 2023	SELL Open market or private sale	$19,977 $11.8 p/Share	1,693 Reduced 1.15%	146,136 Common Stock
Jun 27 2023	SELL Open market or private sale	$3,563 $12.12 p/Share	294 Reduced 0.2%	147,829 Common Stock
Apr 28 2023	SELL Open market or private sale	$9,631 $11.16 p/Share	863 Reduced 0.57%	149,272 Common Stock
Mar 27 2023	SELL Open market or private sale	$5,329 $15.36 p/Share	347 Reduced 0.23%	150,135 Common Stock
Jan 30 2023	SELL Open market or private sale	$18,627 $21.56 p/Share	864 Reduced 0.57%	150,482 Common Stock
Jan 17 2023	BUY Grant, award, or other acquisition	-	101,115 Added 40.05%	151,346 Common Stock
Dec 27 2022	SELL Open market or private sale	$6,448 $14.49 p/Share	445 Reduced 0.88%	50,231 Common Stock
Oct 28 2022	SELL Open market or private sale	$23,672 $21.54 p/Share	1,099 Reduced 2.12%	50,676 Common Stock

Thomas Catinazzo

Chief Financial Officer

Cambridge, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells RLAY shares.

Notify only if

Value

Insider Trading

Get notified when an Relay Therapeutics, Inc. insider buys or sells RLAY shares.

Notify only if

Operation

Value

Type

News

Receive news related to Relay Therapeutics, Inc.

Track Activities on RLAY

Account